Concepedia

Mimi L. Quan

ML

40

Publications

1.8K

Citations

25

H-Index

1991

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Wilmington University

DuPont (United States)

Bristol-Myers Squibb (Germany)

Experimental Station

Mimi L. Quan is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

1991–2020

40

Publications

40

Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-<i>N</i>-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1<i>H</i>-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Mimi L. Quan, Patrick Y. S. Lam, Qi Han et al. · Journal of Medicinal Chemistry · 2004 · 188 citations · Full text

, , +17

Constrictive binding of large guests by a hemicarcerand containing four portals

Mimi L. Quan, Donald J. Cram · Journal of the American Chemical Society · 1991 · 185 citations

, , +13

Discovery of 1-[3-(Aminomethyl)phenyl]-<i>N</i>-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1<i>H</i>-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Shuaige Wang et al. · Journal of Medicinal Chemistry · 2001 · 172 citations · Full text

Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 1

Mimi L. Quan, Ann Y. Liauw, Christopher D. Ellis et al. · Journal of Medicinal Chemistry · 1999 · 80 citations · Full text

Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 2

Mimi L. Quan, Christopher D. Ellis, Ann Y. Liauw et al. · Journal of Medicinal Chemistry · 1999 · 77 citations

Rows per page

1–5 of 40